The potential value of the AIM2 gene as a biomarker of CRC prognosis was also suggested by Professor Tin’s group, who performed an extensive analysis of AIM2 and other NLRs in human CRC by combining the bioinformatics analysis of ten independent, publicly available, databases from the Oncomine® Platform, an online collection of microarrays, with validation experiments using 40 case-matched cancer samples and adjacent healthy control tissues isolated from a cohort of patients from China [26]. The gene discussed is AIM2; the disease is cancer.